

Contents

Contributors

xiii

Preface

xvii

1. Heparin: An essential drug for modern medicine	1
Cui Hao, Hongmei Xu, Lingfan Yu, and Lijuan Zhang	
1. Introduction	2
2. Structure of heparin	2
3. The mechanisms of the heparin	4
4. Clinical studies of heparin	7
5. Concluding remarks	11
Acknowledgments	13
References	13
2. Low molecular weight heparins and their clinical applications	21
Cui Hao, Mojian Sun, Hongmei Wang, Lijuan Zhang, and Wei Wang	
1. Introduction	22
2. Structure of LMWHs	23
3. Clinical uses of LMWHs	25
4. Update on the LMWHs under clinic trials and its potential applications	27
5. Concluding remarks	32
Acknowledgments	33
References	34
3. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide	41
Yiran Zhang, Meng Zhang, Lijuan Tan, Nana Pan, and Lijuan Zhang	
1. Structure and mechanism of Fondaparinux	42
2. Pharmacokinetics and pharmacodynamics of Fondaparinux	44
3. Clinical application of Fondaparinux	46
4. Concluding remarks	49
Acknowledgments	49
Conflict of interest	49
References	50

4. Heparinoids Danaparoid and Sulodexide as clinically used drugs	55
Huaiqian Dou, Aiqin Song, Shaoyou Jia, and Lijuan Zhang	
1. Heparin and heparinoids	56
2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide	59
3. Clinical applications of Danaparoid	61
4. Clinical applications of Sulodexide	64
5. Concluding remarks	67
Acknowledgments	68
References	68
5. Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond—A review of 31 years clinical experiences in China	75
Ming Shan, Ningchuan Feng, and Lijuan Zhang	
1. Introduction	76
2. Preparation, chemical structure, and clinical doses	77
3. Clinical uses and efficacy	78
4. Adverse reactions	81
5. Pharmacodynamics	82
6. Pharmacokinetics	86
7. Future perspectives	86
Acknowledgment	87
Conflicts of interest	87
References	87
6. Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies	95
Jing Wang, Lihua Geng, Yang Yue, and Quanbin Zhang	
1. Introduction	96
2. Preparation and structure of fucoidan	97
3. Pharmacology and mechanism of fucoidan	99
4. Clinical uses and efficacy of fucoidan	103
5. Future perspectives	106
Acknowledgments	106
References	107

7. Marine glycan-derived therapeutics in China	113
Yanyun Gao, Lijuan Zhang, and Wenjie Jiao	
1. Introduction	114
2. Fucoidan (Haikunshenxi capsules)	116
3. Chitin ester (PS916)	117
4. Alginate-derived drugs (PSS, PGMS, 911, PGS, GV971, and HS203)	119
5. Conclusions	127
Acknowledgments	128
Conflicts of interest	128
References	128
Further reading	134
8. An overview of fungal glycan-based therapeutics	135
Dandan Yang, Zijing Zhou, and Lijuan Zhang	
1. Introduction	136
2. Structural studies of fungal glycans	136
3. Fungal glycans-based therapeutics	140
4. Future perspectives	153
Acknowledgments	153
Conflict of interest	153
References	154
9. <i>Ganoderma sinense</i> polysaccharide: An adjunctive drug used for cancer treatment	165
Yiran Zhang, Yifei Jiang, Meng Zhang, and Lijuan Zhang	
1. Introduction	166
2. Structure of <i>G. sinense</i> polysaccharides	166
3. Biological function and clinical practice of <i>G. sinense</i> polysaccharides	167
4. Discussions and conclusion	173
Aknowledgement	174
Conflicts of interest	174
References	174
10. <i>Ganoderma lucidum</i> polysaccharide used for treating physical frailty in China	179
Pengjiao Zeng, Yulong Chen, Lijuan Zhang, and Maoqing Xing	
1. Introduction	181
2. Structure of GLPS	182

3. <i>Ganoderma lucidum</i> -based drugs approved by SFDA in China	183
4. Immunomodulatory and anti-tumor mechanism of GLPS	186
5. Biological activities of GLPS	188
6. Pre- and clinical studies of GLPS	206
7. Concluding remarks	214
Acknowledgment	214
Conflicts of interest	214
References	215
Further reading	219
11. The biological activities of the antitumor drug <i>Grifola frondosa</i> polysaccharide	221
Yanli He, Lijuan Zhang, and Hua Wang	
1. Introduction	223
2. The pharmacological effects of GFP	224
3. Toxicological experiments	254
4. Conclusion	255
Acknowledgment	255
Conflicts of interest	255
References	255
12. Molecular basis for <i>Poria cocos</i> mushroom polysaccharide used as an antitumor drug in China	263
Xiulian Li, Lina Ma, and Lijuan Zhang	
1. Introduction	265
2. Pharmacological activities of PCP	268
3. Clinical efficacy of PCP	286
4. Toxicity	292
5. Future perspectives	292
Acknowledgment	293
Conflict of interest	293
References	293
13. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China	297
Meng Zhang, Yiran Zhang, Lijuan Zhang, and Qingwu Tian	
1. Introduction	299
2. Structure of lentinan	300
3. Biological mechanisms of lentinan	303

	303
	308
	319
	319
	319
14. The efficacy of <i>Polyporus Umbellatus</i> polysaccharide in treating hepatitis B in China	329
Zhihua Guo, Yunjin Zang, and Lijuan Zhang	
1. Introduction	331
2. Clinical trials on chronic hepatitis B and the underlying molecular mechanisms	332
3. The anti-tumor and immuno-enhancing effect of PUPS in lung and liver cancer patients	350
4. Adverse reaction of PUPS	350
5. Conclusion and future perspectives	350
Acknowledgments	354
Conflicts of interest	354
References	354
15. <i>Coriolus versicolor</i> polysaccharopeptide as an immunotherapeutic in China	361
Huaiqian Dou, Yajing Chang, and Lijuan Zhang	
1. Introduction	362
2. Structure of PSP	367
3. Immunomodulatory and antitumor activities of PSP	369
4. Toxicity and side effects of PSP	376
5. Conclusions and future perspectives	377
Acknowledgments	377
Conflicts of interest	377
References	377
16. <i>Tremella</i> polysaccharide: The molecular mechanisms of its drug action	383
Dandan Yang, Yong Liu, and Lijuan Zhang	
1. Introduction	385
2. Structure of TFPS	386
3. TFPS-based drugs approved by SFDA in China	387
4. Pharmacological activities and mechanisms of TFPS	388

5. Clinical studies of TFPS	410
6. Future perspectives	415
Acknowledgments	415
Conflicts of interest	415
References	415
17. The structures and biological functions of polysaccharides from traditional Chinese herbs	423
Pengjiao Zeng, Juan Li, Yulong Chen, and Lijuan Zhang	
1. Introduction	424
2. Extraction, separation, purification and structural analysis method of polysaccharide	425
3. Overview of biological activities of polysaccharides purified from traditional Chinese herbs	428
4. Future perspectives	434
Acknowledgments	438
Conflict of interest	438
References	438
18. Biological mechanisms of glycan- and glycosaminoglycan-based nutraceuticals	445
Yang Tang, Yidi Cui, Ariane De Agostini, and Lijuan Zhang	
1. Introduction	446
2. Terrestrial sources of nutraceutical glycans	447
3. Marine sources of nutraceutical glycans	455
4. Discussions and conclusions	456
Acknowledgments	462
Conflict of interest	462
References	462
19. Glycosylation-dependent antitumor therapeutic monoclonal antibodies	471
Yiran Zhang, Chun Fan, Lijuan Zhang, and Xuexiao Ma	
1. Structures of immunoglobulin	472
2. Glycosylation of IgG and its significance	473
3. Production of therapeutic monoclonal antibodies	477
4. FDA approved antitumor therapeutic monoclonal antibodies	478
5. Conclusions and perspectives	480
Acknowledgments	481
Conflict of interest	481
References	481

20. Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs 487

Jing Fu, Zhongyuan Wu, and Lijuan Zhang

1. Introduction 488
2. Glycosylated low molecular weight drugs (GLMWDs) 489
3. Conclusions and perspectives 512
- Acknowledgments 513
- Conflicts of interest 513
- References 513

Index 523